Home > Riviste > Minerva Urology and Nephrology > Fascicoli precedenti > Minerva Urologica e Nefrologica 2020 April;72(2) > Minerva Urologica e Nefrologica 2020 April;72(2):236-42



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo


ORIGINAL ARTICLE   Free accessfree

Minerva Urologica e Nefrologica 2020 April;72(2):236-42

DOI: 10.23736/S0393-2249.19.03450-7


lingua: Inglese

Pumpkin seeds, Centella asiatica, Boswellia, Helichrysum, acetate vitamin E, Melaleuca alternifolia and hyaluronic acid phytocomplex monotherapy effects in patients with chronic pelvic pain syndrome

Tommaso DI VICO 1 , Jacopo DURANTE 1, Chiara POLITO 1, Alessio TOGNARELLI 1, Domenico CANALE 2, Carolina CAGLIERESI 2, Girolamo MORELLI 3, Riccardo BARTOLETTI 1

1 Department of Translational Research and new Technologies, University of Pisa, Pisa, Italy; 2 Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy; 3 Department of Surgical, Medical and Molecular Pathology, University of Pisa, Pisa, Italy

BACKGROUND: Proxelan® and antibiotics combined therapy was successfully previously used in the treatment of symptoms of patients with chronic prostatitis. Aim of the present study was to investigate the effects of Proxelan® monotherapy on pain symptoms of patients with chronic prostatitis (CP) or chronic pelvic pain syndrome (CPPS) in a prospective pilot study.
METHODS: Thirty consecutive patients with CP/CPPS symptoms younger than 50, without urinary obstruction, total prostate-specific antigen (PSA) <4 ng/mL, negative microbiology testing on prostate fluid and urethral swab, naïve from other treatments during the previous three months were enrolled in a pilot study. IPSS and NIH-CPSI questionnaires were administered to all the patients. Patients could choose to be investigated regarding semen quality and IL6/IL8 seminal markers for inflammatory disease prior and after the therapy course. Proxelan® suppositories were prescribed for each patient for a month with a daily dosage of 1 suppository at bed-time. The primary endpoint of the study included at least a 30% reduction of pain symptoms because similar results can be obtained in each previously investigated placebo group. Effects on semen parameters such as leukocytospermia, spermatozoa concentration and motility, cytokine levels were considered as secondary endpoints.
RESULTS: Subjective pain relief was obtained in all the patients with significant decrease of NIH-CPSI pain items (P=0.04). Urinary symptoms, investigated by IPSS questionnaire, decreased significantly (P=0.04) as well as quality of life items (P=0.04). Leukocytospermia was found in 5/15 patients available for further investigations. IL6 decreased by 11.55% one month after the treatment while sperm motility resulted increased by 17.3%.
CONCLUSIONS: Proxelan® monotherapy may represents a promising valid alternative to combined treatment with antibiotics in patients with CP/CPPS symptoms although the results obtained should be investigated in randomized controlled trials.

KEY WORDS: Prostatitis; Phytotherapy; Cytokines

inizio pagina